Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Malaria as a risk factor for COVID-19 in western Kenya and Burkina Faso
PACTR202009642148520Phase 3Completed
- Sponsor
- Liverpool School of Tropical Medicine
- Start
- Nov 2020
- Modality
- Small Molecules
- Countries
- 2
01
Overview
Phase 3, open-label trial of artemether + lumefantrine and artesunate + pyronaridine in malaria and coronavirus disease 2019 (COVID-19) (2 arms), sponsored by Liverpool School of Tropical Medicine. Primary endpoint: Incidence of SARS-CoV-2 clearance. Started Nov 2020; status: completed.
02
Drugs
artemether + lumefantrineartesunate + pyronaridine
03
Conditions
malariacoronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on PACTR202009642148520.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on PACTR202009642148520.